News First major insurer covers Eisai’s Alzheimer’s drug Leqembi Department of Veterans Affairs will cover the drug for veterans with early-stage Alzheimer's.
News Lilly shares disappointing A4 study results for solanezumab The drug only targets soluble amyloid beta-protein and doesn't clear amyloid plaques.
News FDA sets July verdict date for Leqembi, after adcomm meeting After priority review, regulator will consider upgrading the drug's status to full approval.
News Leqembi still too pricey, says ICER in updated review Side effects create 'uncertainties' as to whether lecanemab's benefits exceed its risks.
News CMS accused of discrimination over Alzheimer’s drug verdict Decision not to revisit coverage decision for amyloid drugs is slammed by patient groups.
News Eisai says early Leqembi rollout exceeds its hopes Eisai didn't reveal sales of its new Alzheimer's disease therapy Leqembi in its third-quarter update, but said the launch was running "ahead of expectations" since the dru
News MHRA unveils big shakeup in UK clinical trials regs Reforms will make applications streamlined and flexible without affecting safety, says agency.
R&D Sponsored An inside guide to unlocking clinical research in the UK An inside guide to unlocking clinical research in the UK
